Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-operative adjuvant nivolumab plus cisplatin-radiotherapy vs standard cisplatin-radiotherapy in high-risk resected squamous cell carcinoma of the head and neck
2017-004936-13Phase 3Active
- Sponsor
- GORTEC
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Disease-free survival. Started Feb 2020; status: active.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-004936-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004936-13.